La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Carmell a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Carmell..

Carmell (NASDAQ:CTCX) Azioni, Catena delle Opzioni

Carmell Therapeutics

Carmell Corp is a bio-aesthetics company that utilizes the Carmell Secretome to support skin and hair health. Its cosmetic skincare product portfolio includes Carmell G.L.E.E and various others in pipeline such as Youth restoring formula, Ultra-brightening formula, Ultra-hydrating formula, and Rapid Recovery formula among others. The company has one operating segment, principally the business of developing and commercializing bio-aesthetics and its bone and tissue healing products.

Carmell Corp

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares traded lower on Monday. The company unveiled <a href="https://www.benzinga.com/pressreleases/25/01/b42813839/intel-extends-leadership-in-ai-pcs-and-edge-computing-at-ces-2025">new AI PC processors at CES 2025</a>.
What Happened: Intel has unveiled a new suite of Intel&nbsp;Core&nbsp;Ultra (Series 2) processors aimed at revolutionizing mobile computing for businesses, creators and enthusiast gamers. Intel&#8217;s latest processors come packed with AI enhancements, increased efficiency and performance improvements.
&#8220;The strength of our AI PC product innovation, combined with the breadth and scale of our hardware and software ecosystem across all segments of the market, is empowering users with a better experience in the traditional ways we use PCs for productivity, creation and communication, while opening up completely new capabilities with over 400 AI features,&#8221; said Michelle Johnston Holthaus, interim co-CEO of Intel and CEO of Intel Products. 
&#8220;And Intel is only going to continue bolstering its AI PC product portfolio in 2025 and beyond as we sample our lead Intel 18A product to customers now ahead of volume production in the second half of 2025.&#8221;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In 2024 — Where Do Tesla, Nvidia, GameStop, Trump Media Stocks Rank?</a>
Intel unveiled new Ultra 2000V series mobile processors for businesses, Core&nbsp;Ultra 200HX and H series mobile processors for AI acceleration, Core Ultra 200U series mobile processors for mobile users, a new Core Ultra 200S series desktop processor portfolio and processors for edge computing. The company also provided updates on its 18A manufacturing and next-generation processor family.
Intel noted that its partnership with Microsoft on Copilot+ PCs aims to continue to advance AI-driven innovation, enhanced security and superior performance into 2025.
Intel Core Ultra 200V series-powered systems with the Intel vPro platform are available at online and in-store retailers as of Monday. Intel Core Ultra 200H and U series-powered systems are expected to become available in February. Intel Core Ultra 200HX series-powered systems are expected to become available in the first half of 2025. Intel Core Ultra 200S series desktop processors and OEM systems will be available through online and in-store retailers beginning Jan. 13.
See Also: <a href="https://www.benzinga.com/25/01/42813592/ai-chip-stocks-nvidia-broadcom-amd-taiwan-semi-micron-super-micro-surge-on-monday-whats-going-on">AI Chip Stocks Nvidia, Broadcom, AMD, Taiwan Semi, Micron, Super Micro Surge Premarket: Whats Going On?</a>
INTC Price Action: <a href="http://benzinga.com/quote/intc">Intel shares</a> initially traded higher Monday morning before pulling back. The stock closed Monday down 3.36% at $19.87, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

News

Movers

INTC

What's Going On With Intel Stock Monday?

Congress gathered on Monday to certify <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">President-elect Donald Trump's election</a> victory under the tightest national security levels possible in a stark reminder of four years ago when the U.S. Capitol <a href="https://www.benzinga.com/government/21/01/19049660/washington-dc-descends-into-anarchy-as-trump-supporters-storm-us-capitol-delay-electoral-college-vot">descended into chaos and violence</a> on Jan. 6, 2021, when lawmakers gathered to certify then-President-elect Joe Biden's win.
<h2 class="wp-block-heading">Things Are Different This Jan. 6: &#8216;Democracy Prevails&#8217; </h2>
When Vice President Kamala Harris walked into the Senate chamber on Monday to undertake the traditional role of certifying the national election, she issued a simple declaration when asked about the procedure by NBC News. "Democracy prevails," she said. 
Harris oversaw the process as four senators confirmed each state&#8217;s votes, which she lost to Trump, resulting in his return to the White House. Once the total vote reached a threshold, Harris certified Trump&#8217;s election victory.
&#8220;I do believe very strongly that America&#8217;s democracy is only as strong as our willingness to fight for it &#8230; Otherwise, it is very fragile, and it will not be able to withstand moments of crisis. And today, America&#8217;s democracy stood,&#8221; Harris said in comments after the count, <a href="https://abcnews.go.com/Politics/congress-meets-certify-trumps-2024-election-victory/story?id=117380065">reported</a> ABC News
NBC <a href="https://www.nbcnews.com/politics/kamala-harris/kamala-harris-approaching-certifying-election-loss-trump-rcna186298">reported</a> that Harris broke into a smile upon receiving a standing ovation from the Democratic party when her own vote total for the November election was read. The totals were 75,000,783 votes for Harris to Trump's 77,285,106.
<h2 class="wp-block-heading">Former VP Mike Pence Seemed Calmer This January 6</h2>
Trump&#8217;s former Vice President, Mike Pence, who faced <a href="https://www.cnn.com/videos/politics/2021/01/15/mike-pence-close-call-capitol-riot-foreman-vpx.cnn">threats </a>from rioters during the Jan. 6 attack on the Capitol—an event some allege <a href="https://www.benzinga.com/news/23/10/35528275/experts-testify-on-jan-6-in-trumps-14th-amendment-colorado-case-ex-president-expressed-messages-that">was incited by Trump</a>—sounded much calmer this year.
"The peaceful transfer of power is the hallmark of our democracy and today, members of both parties in the House and Senate along with the vice president certified the election of our new president and vice president without controversy or objection," he <a href="https://x.com/Mike_Pence/status/1876340275037266113">said</a> in on X.  
In the days and weeks after the Jan. 6 Capitol riot, seven people, including three law enforcement officers, lost their lives, according to a <a href="https://www.hsgac.senate.gov/imo/media/doc/HSGAC&amp;RulesFullReport_ExaminingU.S.CapitolAttack.pdf" target="_blank" rel="noreferrer noopener">bipartisan</a> Senate report. 
This Jan 6, 2025, the confirmation process went off without incident and was over in about 30 minutes.
Now read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42827796/maga-meme-coin-surges-20-boosting-donald-trumps-crypto-portfolio-11-9m">MAGA Meme Coin Surges 20%, Boosting Donald Trump&#8217;s Crypto Portfolio $11.9M</a></li>
</ul>
Photo: miss.cabul/Shutterstock.com

Government

Politics

Trump Confirmed President By VP Harris As Pence Hails 'Peaceful Transfer' This Jan. 6

Legendary investor Warren Buffett had a 2024 to remember with Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) reaching the $1 trillion market capitalization milestone for <a href="https://www.benzinga.com/general/education/24/08/40652464/warren-buffett-celebrates-94th-birthday-with-1-trillion-market-cap-milestone-a-look-back-at-hig">the first time.</a>
During the year, Buffett&#8217;s Berkshire Hathaway also outperformed the S&amp;P 500, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>). 
Overall, Berkshire Hathaway stock was up 27.1% in 2024 versus a 24.1% gain for SPDR S&amp;P 500 ETF Trust, according to data from <a href="https://www.macrotrends.net/stocks/charts/BRK.B/berkshire-hathaway/stock-price-history">Macrotrends</a>. That&#8217;s despite Berkshire Hathaway offloading top-performing Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) stock<a href="https://www.benzinga.com/markets/equities/24/12/42666459/warren-buffett-once-called-berkshire-the-opposite-of-those-who-hurry-to-sell-now-hes-offloading-apple-and-snapping-up-occidental-petroleum-amid-a-20-drop"> during the year.</a>
Here's a look at the gains of Berkshire Hathaway B shares vs. the SPY over the last 20 <a href="https://www.macrotrends.net/stocks/charts/SPY/spdr-s-p-500-etf/stock-price-history">years</a>:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>YEAR</td>
<td>BRK-B</td>
<td>SPY</td>
<td>WINNER</td>
</tr>
<tr>
<td>2024</td>
<td>+27.1%</td>
<td>+24.1%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2023</td>
<td>+15.5%</td>
<td>+26.7%</td>
<td>SPY</td>
</tr>
<tr>
<td>2022</td>
<td>+3.3%</td>
<td>-17.5%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2021</td>
<td>+29.0%</td>
<td>+28.7%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2020</td>
<td>+2.4%</td>
<td>+18.4%</td>
<td>SPY</td>
</tr>
<tr>
<td>2019</td>
<td>+10.9%</td>
<td>+31.2%</td>
<td>SPY</td>
</tr>
<tr>
<td>2018</td>
<td>+3.0%</td>
<td>-4.6%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2017</td>
<td>+21.6%</td>
<td>+21.7%</td>
<td>SPY</td>
</tr>
<tr>
<td>2016</td>
<td>+23.4%</td>
<td>+12.0%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2015</td>
<td>-12.1%</td>
<td>+1.3%</td>
<td>SPY</td>
</tr>
<tr>
<td>2014</td>
<td>+26.6%</td>
<td>+13.5%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2013</td>
<td>+32.2%</td>
<td>+32.3%</td>
<td>SPY</td>
</tr>
<tr>
<td>2012</td>
<td>+17.6%</td>
<td>+16.0%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2011</td>
<td>-4.8%</td>
<td>+1.9%</td>
<td>SPY</td>
</tr>
<tr>
<td>2010</td>
<td>+21.9%</td>
<td>+15.1%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2009</td>
<td>+2.2%</td>
<td>+26.4%</td>
<td>SPY</td>
</tr>
<tr>
<td>2008</td>
<td>-32.1%</td>
<td>-36.8%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2007</td>
<td>+29.2%</td>
<td>+5.1%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2006</td>
<td>+24.9%</td>
<td>+15.9%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2005</td>
<td>-.02%</td>
<td>+4.8%</td>
<td>SPY</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">The chart shows which stock performed better in the right-hand column.</figcaption></figure>
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/25/01/42798998/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
<h3 class="wp-block-heading">Key Points: Buffett Vs. SPY</h3>
Berkshire Hathaway beat the S&amp;P 500 in 2024, but significantly underperformed in 2023.
The last down year for the S&amp;P 500 came in 2022 with the SPY down 17.5% for the year. For Berkshire Hathaway, the last down year was in 2015, with a 12.1% decline.
Over the last 20 years, the best return for the SPY was +32.3% in 2013, just outperforming Berkshire Hathaway at +32.2% in the same year.
A look at the worst year also sees SPY win with a 36.8% decline in 2008 compared to a 32.1% decline for Berkshire Hathaway in the same year.
Overall, in the last 20 years, Buffett has won the head-to-head battle 11 times with SPY winning nine times. 
Taking the average return of the last 20 years, Berkshire Hathaway leads at 12.1% to 11.5%.
More importantly, the 20-year return is +669% for Berkshire Hathaway compared to a 20-year return of +621.2% for SPY, adjusted for dividends.
When it comes to investing in the SPY vs. Berkshire Hathaway, the Oracle of Omaha leads the battle across many metrics over the last 20 years, including overall returns.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/12/42734838/warren-buffetts-chilling-warning-to-employees-lose-a-shred-of-reputation-for-the-firm-and-i-will-be-ruthless">Warren Buffett&#8217;s Chilling Warning To Employees: &#8216;Lose A Shred Of Reputation For The Firm And I Will Be Ruthless&#8217;</a></li>
</ul>
Image: Shutterstock

Broad U.S. Equity ETFs

Education

Management

Trading Ideas

ETFs

AAPL

Warren Buffett Beats S&P 500 In 2024, How Oracle Of Omaha's Returns Compare Over Past 20 Years

Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares are trading higher in Monday&#8217;s after-hours session after the company announced a CEO transition and <a href="https://www.benzinga.com/pressreleases/25/01/b42830392/ulta-beauty-announces-ceo-transition">updated its near-term outlook</a>.
What Happened: After the market close on Monday, Ulta announced that Dave Kimbell will retire as CEO and step down from the company&#8217;s board, effective immediately.
President and COO Kecia Steelman will succeed Kimbell as president and CEO, effective as of Monday. Steelman will also join the company&#8217;s board. 
&#8220;Kecia is a world-class business executive with deep beauty and retail expertise, an unwavering commitment to effective execution, and a profound passion for our guests and associates. She has been instrumental in developing our recently refreshed strategic framework, and we are confident that she is the right person to lead Ulta Beauty forward,&#8221; said Lorna Nagler, chair of Ulta Beauty&#8217;s board.
See Also: <a href="https://www.benzinga.com/25/01/42825782/bath-body-works-loyalty-program-shines-in-holiday-sales-says-analyst">Bath &amp; Body Works Undervalued: Goldman Sachs Sees Upside Amid Strong Candle Day Performance</a>
In addition to the CEO transition, Ulta updated its fourth-quarter guidance to reflect stronger-than-expected performance during the holiday season. 
The company now expects comparable sales to &#8220;increase modestly.&#8221; Ulta also said it expects operating margin to be above the high-end of the company&#8217;s previous expected range of&nbsp;11.6%&nbsp;to&nbsp;12.4% of sales. 
Ulta is scheduled to report fourth-quarter financial results on March 13. Analysts currently expect the company to report earnings of $6.73 per share and revenue of $3.4 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;I am confident the strategic priorities we shared last fall will enable us to capture greater market share in beauty and wellness and deliver long-term profitable growth, and I am excited to lead our outstanding teams as we unlock even greater advantages of our operating model, drive best-in-class execution, and position Ulta Beauty for our next chapter of growth as the beauty destination for a lifetime,&#8221; Steelman said. 
ULTA Price Action: <a href="http://benzinga.com/quote/ulta">Ulta Beauty shares</a> were up 2.48% after hours, trading at $442 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Guidance

After-Hours Center

General

ULTA

Ulta Beauty Stock Is Rising After Hours: Here's Why

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 15 years by 2.69% on an annualized basis producing an average annual return of 14.37%. Currently, Graphic Packaging Holding has a market capitalization of $7.94 billion. 
Buying $1000 In GPK: If an investor had bought $1000 of GPK stock 15 years ago, it would be worth $7,385.47 today based on a price of $26.44 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736199908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=Stoke+Therapeutics%2C+Inc.&amp;index=1&amp;md5=454f1331ad469e0bb2ff820d8c29374c">Stoke Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors &amp; News section of Stoke's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;index=2&amp;md5=0cb1b30b6a3643c6103e41277dc36c53">https://investor.stoketherapeutics.com/</a>. Research analysts who plan to join the call and participate in the Q&amp;A session may register <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBIfb7a43c079834c3cb6a0813f54c1059e&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=7af8fd1c74d79d04b91cc2894bac615b">here</a> to receive the dial-in details and a unique PIN. For all others, the listen-only webcast can be accessed by clicking <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fmj8c7ajk&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=8eeec19293664ff83d3ffc6172d6dc34">here</a>. A replay of the webcast will be archived and available for at least 90 days following the event.

Biotech

Events

STOK

Stoke Therapeutics To Host Webcast To Discuss Successful Global Regulatory Alignment For A Phase 3 Study Of Zorevunersen As Potentially The First Disease Modifying Medicine For Dravet Syndrome On January 7, 2025 At 8:00am Eastern Time

Equus Appoints Fraser Atkinson As Chairman

– Mollie Leoni, M.D. promoted to Chief Medical Officer –
– Francis Burrows, Ph.D. promoted to Chief Scientific Officer –
– Stephen Dale, M.D., steps down as CMO and Head of R&amp;D to prioritize personal health –
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Mollie Leoni, M.D., has been promoted to Chief Medical Officer after serving as Executive Vice President of Clinical Development and clinical lead for the Company's ziftomenib program since 2020. In addition, Francis Burrows, Ph.D., has been promoted to Chief Scientific Officer after leading the Company's translational research efforts for the past nine years. Stephen Dale, M.D., has stepped down as Chief Medical Officer, effective as of January 2, 2025, to focus on recovery from personal health challenges.

KURA

Kura Oncology Announces Senior Executive Promotions; Mollie Leoni, Promoted To Chief Medical Officer; Stephen Dale Steps Down As CMO And Head Of R&D To Prioritize Personal Health

ENVX

Enovix Completes Site Acceptance Testing Of Fab2

Sheridan C. Swords, previously executive vice president, commercial liquids and natural gas gathering and processing, is assuming the newly created position of executive vice president and chief commercial officer.&nbsp;
 &nbsp;

ONEOK Names Randy N. Lentz To Newly Created Position Of Executive Vice President And COO;

<ul>
<li>Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo</li>
<li>Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases</li>
<li>Company reorganization supports evolution of ctLNP-enabled strategy and buildout of clinical capabilities ahead of first IND expected in 2H 2026</li>
</ul>
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=027Hc0iV9b3bn31fIYu-D_K2UCwWK-kHIEeCWObZ_SYoKcLmk_FTbqmyuakhho9D_puGTMCU4fcrMVn_xRE377LIYsBdVqYhVAkwMl-lP1bnLAothOYz1lzNzcCUGCtUZ-ql2y8lzaklBO-Z3eX5LvyqZqdKorEbxHNadzB1MVHlTX8vWFpNiycqI5P_fTVwJyGqJwJziyyNlnFNSvbQ7DNZjz3EI11B6LKd-_LuIsOuQVtCVBoqV7eVloXCn-mLYI1FrHvSpQslCrcpjngxjg==">Generation Bio Co.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics to silence disease-driving targets in T cells.

GBIO

Generation Bio To Apply ctLNP Delivery Technology To Develop siRNA Therapeutics For T Cell-Driven Autoimmune Diseases

During the interim period until the transaction closes, Ansys will continue to offer Ansys PowerArtist as part of its product line, and is committed to providing the same high-quality service its customers have come to expect.

Asset Sales

ANSS

Ansys Says Sale Of PowerArtist Is Not Material To Its Financials; Terms Of Agreement Were Not Disclosed

Ansys and Synopsys determined that the sale of PowerArtist was necessary to obtain regulatory approval for Synopsys' proposed acquisition of Ansys.

KEYS

SNPS

Ansys Enters Definitive Agreement For Sale Of Its PowerArtist Business To Keysight Technologies

<ul>
<li>Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks</li>
<li>Overall, DNL343 was found to be safe and well tolerated</li>
<li>Additional analyses, including neurofilament light (NfL) and other fluid biomarkers, prespecified sub-group analyses and analyses from the active treatment extension period are expected later in 2025 &nbsp;</li>
</ul>

DNLI

Denali Therapeutics Announces Topline Results For Regimen G Evaluating eIF2B Agonist DNL343 In Phase 2/3 HEALEY ALS Platform Trial; Study Did Not Meet Primary Endpoint

NNN REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>), a real estate investment trust, today announced that Kevin B. Habicht, Executive Vice President, Chief Financial Officer, Assistant Secretary, Treasurer and the Company's principal financial officer, will retire and step down as a member of the Board of Directors effective March 31, 2025.&nbsp; Vincent H. Chao will join NNN as Executive Vice President on January 9, 2025, and assume the positions of Chief Financial Officer, Assistant Secretary and Treasurer and serve as the Company's principal financial officer effective April 1, 2025.
Mr. Habicht has served as Executive Vice President and Chief Financial Officer of the Company since December 1993, and as Treasurer of the Company since January 1998 and as a director of the Company since June 2000. Mr. Habicht served as Secretary of the Company from January 1998 to May 2003.

NNN REIT Announces Kevin B. Habicht, Executive Vice President, CFO, Assistant Secretary, Treasurer And The Co's Principal Financial Officer, Will Retire, Effective March 31, 2025. Vincent H. Chao Will Join As Executive Vice President On January 9, 2025, And Assume The Positions Of CFO, Assistant Secretary And Treasurer And Serve As The Co's Principal Financial Officer Effective April 1, 2025

Jack A. Hockema, Executive Chair of the Board of Directors and Chair of the Executive Committee of the Board, notified the Board of his decision to retire as a director of the Company, effective January 1, 2025.&nbsp;
&nbsp;

KALU

Kaiser Aluminum Names Keith A. Harvey,  Company's President, CEO And A Director, As Chairman Of The Board

Contracts

MPTI

MtronPTI Receives Over $10M Production Contract For A US Defense Program

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 12.62% on an annualized basis producing an average annual return of 25.44%. Currently, Krystal Biotech has a market capitalization of $4.45 billion. 
Buying $1000 In KRYS: If an investor had bought $1000 of KRYS stock 5 years ago, it would be worth $3,017.82 today based on a price of $155.81 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736199008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS

Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) and Southwest Airlines Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) shares traded higher on Monday. Here&#8217;s what <a href="https://www.benzinga.com/general/travel/25/01/42809678/delta-southwest-american-and-others-airlines-halt-over-1300-flights-on-monday-after-severe-winter-storm">you need to know</a>.
What To Know: <a href="https://www.benzinga.com/general/travel/24/12/42705878/airline-stocks-outperform-tech-in-2024-holiday-travel-expected-to-see-records-this-year">Airlines</a> and other travel-related stocks moved higher on Monday after Transportation Security Administration (TSA) traveler screening data showed record travel figures for the end of 2024.
Near the end of last week, TSA <a href="https://x.com/TSA/status/1875202022737412371">posted</a> on X that it screened almost 39 million individuals from Dec. 19 through Jan. 2, marking its &#8220;busiest end of year travel period ever.&#8221; For all of 2024, TSA said officers screened a record 904 million people at airport checkpoints across the nation.
The government agency <a href="https://www.tsa.gov/travel/passenger-volumes/2024">reported</a> that 2,172,907 travelers were screened on New Year&#8217;s Eve, 2,039,342 were screened on Christmas and 1,551,896 were screened on Thanksgiving.
The increase in TSA screenings indicates strong demand for air travel during the holiday season, which may boost ticket sales and revenue for airlines. Additionally, the high number of passengers highlights the resilience of the travel industry, suggesting continued post-pandemic growth.
Investors won&#8217;t have to wait long to get holiday travel data from the airlines. Notably, Delta is expected to release 2024 fourth-quarter and fiscal-year earnings at the end of the week. Analysts expect quarterly earnings per share of $1.76 and revenue of $14.19 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>. Several other airlines are scheduled to report earnings in the coming weeks. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42828238/gemini-resolves-cftc-lawsuit-with-5m-settlement-over-bitcoin-futures-misstatements">Gemini Resolves CFTC Lawsuit With $5M Settlement Over Bitcoin Futures Misstatements</a>
DAL, AAL, LUV Price Action: Delta shares shares closed Monday up 1.75% at $60.03, American shares closed the day up 3.24% at $17.52 and Southwest shares closed up 0.62% at $33.82, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image via Shutterstock

Travel

What's Going On With Delta, American And Southwest Airlines Shares Monday?

APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) today announced key updates to its executive leadership and corporate officers.
Clay Bretches, executive vice president, Operations, has announced plans to retire July 1, 2025. As part of its commitment to maintaining excellence in operations, the company has launched an internal and external search for a new leader to drive continued innovation and operational efficiency. Bretches will remain with the organization and help ensure a smooth transition to a new leader, anticipated in the first half of 2025.

APA Corporation Announces Clay Bretches, Executive Vice President, Operations, Has Announced Plans To Retire July 1, 2025

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Carmell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctcx-stock-quote/">CTCX</a>) just reported results for the first quarter of 2024.<ul><li>Carmell Therapeutics reported earnings per share of -16 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ctcx-stock-earnings-carmell-therapeutics-for-q1-of-2024/">CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Carmell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctcx-stock-quote/">CTCX</a>) just reported results for the fourth quarter of 2023.<ul><li>Carmell Therapeutics reported earnings per share of $1.35.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ctcx-stock-earnings-carmell-therapeutics-for-q4-of-2023/">CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023

Carmell appoints Kendra Bracken-Ferguson as CEO

An update from Carmell Therapeutics (CTCX) is now available. Carmell Corporation has announced a major leadership change with Rajiv S. Shukla stepp...

Carmell Therapeutics Announces CEO Transition and New Leadership Incentives

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Carmell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctcx-stock-quote/">CTCX</a>) just reported results for the second quarter of 2024.<ul><li>Carmell Therapeutics reported earnings per share of -16 cents.</li><li>The company reported revenue of $12,320.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ctcx-stock-earnings-carmell-therapeutics-for-q2-of-2024/">CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q2 2024

Carmell Therapeutics ( ($CTCX) ) has shared an announcement. Carmell Corporation is making waves in the skincare industry with its revolutionary Ca...

Carmell Therapeutics Unveils Innovative Skincare Breakthroughs

Carmell entered into a securities purchase agreement with new and existing investors for the issuance and sale of 8,065,210 shares of its common st...

Carmell Therapeutics to sell 8.065M shares at 23c in private placement

Carmell announces PIPE investment, shares up more than 20%

Carmell Corporation (CTCX) announced that it entered into a definitive purchase agreement with PMGC Holdings (ELAB) and its wholly owned subsidiary...

Comments

Carmell

Carmell (CTCX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO